Skip to main content
Shuttle Pharmaceuticals Holdings, Inc. logo

Shuttle Pharmaceuticals Holdings, Inc. — Investor Relations & Filings

Ticker · SHPH ISIN · US8256933024 US Manufacturing
Open in API
Filings indexed 266 across all filing types
Latest filing 2025-09-08 Board/Management Inform…
Country US United States of America
Listing US SHPH

About Shuttle Pharmaceuticals Holdings, Inc.

https://shuttlepharma.com/

Shuttle Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on developing novel therapies to improve outcomes for cancer patients. The company's mission is to enhance the effectiveness of radiation therapy (RT) by developing drugs that sensitize cancer cells to radiation while protecting adjacent healthy tissues, thereby increasing cure rates and improving quality of life. Its lead product candidate, Ropidoxuridine, is an orally available radiation sensitizer in Phase II clinical development. The pipeline also includes a portfolio of preclinical selective histone deacetylase (HDAC) inhibitors. Additionally, Shuttle is developing diagnostic technologies, including a pretreatment blood test for prostate cancer patients to help predict treatment success and inform therapeutic decisions.

Recent filings

Filing Released Lang Actions
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 8, 2025, by Shuttle Pharmaceuticals Holdings, Inc. The key content is the appointment of a new director, Adam Chambers, to the company's Board of Directors. The document details the director's background and any related party transactions. There are no financial statements or detailed financial data presented. The primary focus is on management/board changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is 4042 characters, which is relatively short and consistent with a Form 8-K announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2025-09-08 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated August 31, 2025, by Shuttle Pharmaceuticals Holdings, Inc. The key content is the announcement of the resignation of a director, Steven Richards, with no disagreements cited. The document is short (3503 characters) and focuses solely on a change in the company's board of directors. This matches the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management. There is no financial data or other report content present, so it is not an Annual Report, Earnings Release, or similar. Therefore, the correct classification is MANG with high confidence.
2025-09-05 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-08-15 English
4
Director's Dealing
2025-08-13 English
4
Director's Dealing
2025-08-13 English
Director's Dealing 2025
Director's Dealing
2025-08-13 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.